Christopher Ryan Sullivan

Chief Financial Officer

Christopher Ryan Sullivan (Chief Financial Officer) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Avalo Therapeutics, Inc. (AVTX). The largest single filing was $1.4M of AVTX (68,976 sh across 2 lots, as filed), executed Aug 17.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 7 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$3.6M

shares × price, as filed

Last traded

Sep 16

Filed Sep 18

Median ADV $28.3M across their filed names

Open performance→

Volume by month

Buys $0 Sells $3.6M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 7 filings

Sector per market data · by filing · past 12 months

Most traded names

AVTX

Avalo Therapeutics, Inc. AVTX · 0 buys · 7 sells 7 filings

Recent filings

AVTXSALE Avalo Therapeutics, Inc. View filing → $202K
12,394 sh × $16.33
Exec Sep 16
Filed Sep 18 · 4:10 PM ET AVTXSALE Avalo Therapeutics, Inc. View filing → $179K
10,185 sh × $17.62
Exec Sep 10
Filed Sep 11 · 4:10 PM ET AVTXSALE Avalo Therapeutics, Inc. View filing → $1.4M
68,976 sh across 2 lots
Exec Aug 17
Filed Aug 19 · 4:10 PM ET AVTXSALE Avalo Therapeutics, Inc. View filing → $449K
18,606 sh × $24.12
Exec May 7
Filed May 11 · 5:30 PM ET AVTXSALE Avalo Therapeutics, Inc. View filing → $893K
44,300 sh across 4 lots
Exec May 6
Filed May 7 · 5:30 PM ET AVTXSALE Avalo Therapeutics, Inc. View filing → $223K
16,915 sh across 2 lots
Exec Apr 29
Filed May 1 · 5:30 PM ET AVTXSALE Avalo Therapeutics, Inc. View filing → $231K
13,679 sh across 2 lots
Exec Apr 1
Filed Apr 3 · 5:30 PM ET